View Item 
        •   Utrecht University Student Theses Repository Home
        • UU Theses Repository
        • Theses
        • View Item
        •   Utrecht University Student Theses Repository Home
        • UU Theses Repository
        • Theses
        • View Item
        JavaScript is disabled for your browser. Some features of this site may not work without it.

        Browse

        All of UU Student Theses RepositoryBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

        The Role of Patient-Reported Outcomes in Marketing Authorization Applications and Product Labelling (2018-2020)

        Thumbnail
        View/Open
        MA203_Thesis_Noral_AlMugoter_5532140.pdf (1.579Mb)
        Publication date
        2022
        Author
        Al-Mugoter, Nora
        Metadata
        Show full item record
        Summary
        BACKGROUND Little is known about the role Patient-Reported Outcomes (PROs) play in, the main clinical studies, the benefit-risk assessment, product labelling, and which determinants play a role herein. METHOD We evaluated the European Public Assessment Reports (EPARs) of new medicinal agents with a regulatory decision (approved or refused) by the EMA between January 1, 2018 and December 31, 2020. The primary and secondary endpoints of the main studies, benefit-risk balance, effect tables (results that have a strong influence on the assessment) and SmPC (for patient care decision-making) were evaluated for any mention of PROs. RESULTS A total of 149 products met our criteria. Of these, 84 (56.40%) mentioned PROs. PROs were used significantly more as a secondary endpoint and contributed significantly more to patient care decision-making by chronic treatment compared to acute and preventive treatment. Furthermore, the disease category played a significant role in PRO use. For example, by respiratory conditions, PROs weighed in on 100% of the effect tables and SmPC. In contrast to infectious disease, where PROs weighed in on 5%, and 0% of their effect tables and SmPC, respectively. Moreover, PROs from blinded studies contributed significantly more to patient care decision-making compared to open-label studies 3.836 (95% Cl 1.802-8.167, p < 0.01). CONCLUSION In conclusion, different product determinants play a role in the utilization and contribution of PROs to the assessment and patient care decision-making. Overall, more PRO claims are being approved by the EMA and a gradual increase are seen in their contribution to support drug licensing. They are weighing in more and more on the benefit-risk balance assessment.
        URI
        https://studenttheses.uu.nl/handle/20.500.12932/490
        Collections
        • Theses
        Utrecht university logo